Randomized Trials between Behenoyl Cytarabine and Cytarabine in Combination Induction and Consolidation Therapy, and with or Without Ubenimex after Maintenance/Intensification Therapy in Adult Acute Myeloid Leukemia

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 204-213

  Kobayashi, T ^a   Miyawaki, S ^b   Tanimoto, M ^b   Kuriyama, K ^b   Murakami, H ^b   Yoshida, M ^b   Minami, S ^b   Minato, K ^b   Tsubaki, K ^b   Ohmoto, E ^b   Oh, H ^b   Jinnai, I ^b   Sakamaki, H ^b   Hiraoka, A ^b   Kanamaru, A ^b   Takahashi, I ^b   Saito, K ^b   Naoe, T ^b   Yamada, O ^b   Asou, N ^b   Kageyama, S ^b   Emi, N ^b   Matsuoka, A ^b   Tomonaga, M ^b   Saito, H ^b   Ueda, R ^b   Ohno, R ^b   more..

^a MIE UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BESTATIN; CYTARABINE; ENOCITABINE; MERCAPTOPURINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEPSIS; SURVIVAL TIME; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUCINE; LEUKEMIA, MYELOID; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISOLONE; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030030928     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.204     Document Type: Article

References (37)

1. 4-behenoyl-1-β-D-arabinofuranosylcytosine in blood cells. Gann 74:445-451, 1983
2. 4-behenoyl-1-β-D-arabinofuranosylcytosine (BHAC) in leukemia, in Kimura K, Yamada K, Frei E III, et al (eds): Cancer Chemotherapy: Challenges for the Future, vol 3. Tokyo, Japan, Excerpta Medica, 1988, pp 289-295
3. 4-behenoyl-1-β-D-arabinofuranosylcytosine in patients with acute leukemia. Cancer Res 43:3412-3416, 1983
4. 4-behenoyl-1-β-D-arabinofuranosylcytosine. Med Oncol Tumor Pharmacother 3:15-24, 1986
5. 4-behenoyl-1-β-D-arabinofuranosylcytosine. Cancer 56:1913-1917, 1985
6. Ohno R, Kato Y, Nagura E, et al: Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length. J Clin Oncol 4:1740-1747, 1986
7. Ohshima T, Takeuchi J: Short term intensive chemotherapy regimens for adult acute myeloid leukemia-DCMP-85 vs DBMP-85, in Kimura K, Yamada K, Frei E III, et al (eds): Cancer Chemotherapy: Challenges for the Future, vol 3. Tokyo, Japan, Excerpta Medica, 1988, pp 153-159
8. Kyo T, Dohy H: Treatment of acute non-lymphocytic leukemia with alternating non-cross resistant chemotherapy. Acta Haematol Jpn 51:1641-1652, 1988
9. Yoshida M, Suda K, Tsuboyama A, et al: Behenoyl cytosine arabinoside, aclacinomycin A, 6-mercaptopurine, and prednisone combination therapy for acute non-lymphcytic leukemia in adults. Eur J Haematol 43:1-6, 1989
10. Kawamura S, Mikami T, Sawada Y, et al: An eight year experience with gradually longer interval postremission therapy for adults with acute leukemia. Tohoku J Exp Med 158:17-24, 1989
11. Ohno R, Tomonaga M, Kobayashi T, et al: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J med 323:871-877, 1990
12. Ohno R, Yokomaku S, Okumura M, et al: Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leukemia in adults. Int J Hematol 54:487-493, 1991
13. Ohno R, Kobayashi T, Tanimoto M, et al: Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. Cancer 71:3888-3895, 1993
14. Ohno R, Yoshida H, Fukutani H, et al: Multi-institutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 7:1722-1727, 1993
15. Nagura E, Kimura K, Yamada K, et al: Nationwide randomized comparative study of daunomycin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia. Cancer Chemother Pharmacol 34:23-29, 1994
16. Ohno R, Naoe T, Kanamaru A, et al: A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 83:2086-2092, 1994
17. Umezawa H, Aoyagi T, Suda H, et al: Bestatin, an inhibitor of aminopeptidase B produced by actinomycetes. J Antibiotics 29:97-99, 1976
18. Ota K: Review of ubenimex (Bestatin): Clinical research. Biomed Pharmacother 45:55-60, 1991
19. Ota K, Kurita S, Yamada K, et al: Immunotherapy with Bestatin for acute nonlymphocytic leukemia in adults. Cancer Immunol Immunother 23:5-10, 1986
20. Rai KR, Holland JF, Glidewell OJ, et al: Treatment of acute myeloid leukemia: A study by Cancer and Leukemia Group B. Blood 58:1203-1212, 1981
21. Foon KA, Gale RP: Controversies in the therapy of acute myelogenous leukemia. Am J Med 72:963-979, 1982
22. Buchner T, Urbanitz D, Hiddemann W, et al: Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of German AML Cooperative Group. J Clin Oncol 3:1583-1589, 1985
23. Preisler H, Davis RB, Kirshner J, et al: Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B study. Blood 69:1441-1449, 1987
24. Wolff SN, Herzig RH, Fay JW, et al: High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: Long-term follow-up and results. J Clin Oncol 7:1260-1267, 1989
25. Champlin R, Gajewski J, Nimer S, et al: Postremission chemotherapy for adult with acute myelogenous leukemia: Improved survival with high-dose cytarabine and daunorubicin consolidation treatment. J Clin Oncol 8:1199-1206, 1990
26. Phillips GL, Reece DE, Shepherd JD, et al: High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 77:1429-1435, 1991
27. Cassileth PA, Lynch E, Hines JD, et al: Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79:1924-1930, 1992
28. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903, 1994
29. Champlin R, Gale RP: Acute myelogenous leukemia: Recent advances in therapy. Blood 69:1551-1562, 1987
30. Zittoun R, Jehn U, Fiere D, et al: Alternating v repeated postremission treatment in adult acute myelogenous leukemia: A randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. Blood 73:896-906, 1989
31. Biaise D, Maraninchi D, Archimbaud E, et al: Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: A randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: A report from the Groupe d'Etudes de la Greffe de Moelle Osseuse. Blood 79:2578-2582, 1992
32. Archimbaud E, Thomas X, Michallet M, et al: Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J Clin Oncol 12:262-267, 1994
33. Zittoun RA, Mandelli F, Willemze R, et al: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217-223, 1995
34. Urabe A, Mutoh Y, Mizoguchi H, et al: Ubenimex in the treatment of acute nonlymphocytic leukemia in adults. Ann Hematol 67:63-66, 1993
35. Foa R: Does interleukin-2 have a role in the management of acute leukemia? J Clin Oncol 11:1817-1825, 1993
36. Look AT, Ashmun RA, Shapiro LH, et al: Human myeloid plasma membrane glycoprotein CD13(gp150) is identical to aminopeptidase N. J Clin Invest 83:1299-1307, 1989
37. Ashmun RA, Look AT: Metalloprotease activity of CD13/ aminopeptidase N on the surface of human myeloid cells. Blood 75:462-469, 1990